Literature DB >> 25949931

Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.

Maurizio Salvadori1, Giuseppina Rosso1, Elisabetta Bertoni1.   

Abstract

Complement cascade is involved in several renal diseases and in renal transplantation. The different components of the complement cascade might represent an optimal target for innovative therapies. In the first section of the paper the authors review the physiopathology of complement involvement in renal diseases and transplantation. In some cases this led to a reclassification of renal diseases moving from a histopathological to a physiopathological classification. The principal issues afforded are: renal diseases with complement over activation, renal diseases with complement dysregulation, progression of renal diseases and renal transplantation. In the second section the authors discuss the several complement components that could represent a therapeutic target. Even if only the anti C5 monoclonal antibody is on the market, many targets as C1, C3, C5a and C5aR are the object of national or international trials. In addition, many molecules proved to be effective in vitro or in preclinical trials and are waiting to move to human trials in the future.

Entities:  

Keywords:  Complement and glomerulopathies; Complement and renal transplantation; Complement cascade; Eculizumab; Targeting complement

Year:  2015        PMID: 25949931      PMCID: PMC4419127          DOI: 10.5527/wjn.v4.i2.169

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  150 in total

1.  Eculizumab in severe Shiga-toxin-associated HUS.

Authors:  Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer
Journal:  N Engl J Med       Date:  2011-05-25       Impact factor: 91.245

Review 2.  Therapeutic inhibition of the complement system.

Authors:  S C Makrides
Journal:  Pharmacol Rev       Date:  1998-03       Impact factor: 25.468

3.  The effect of C1 inhibitor on myocardial ischemia and reperfusion injury.

Authors:  Fengxin Lu; Stacey M Fernandes; Alvin E Davis
Journal:  Cardiovasc Pathol       Date:  2012-06-16       Impact factor: 2.185

Review 4.  Membranous nephropathy: recent travels and new roads ahead.

Authors:  Laurence H Beck; David J Salant
Journal:  Kidney Int       Date:  2010-02-24       Impact factor: 10.612

5.  Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.

Authors:  Gema Ariceta; Beatriz Arrizabalaga; Mireia Aguirre; Elvira Morteruel; Margarita Lopez-Trascasa
Journal:  Am J Kidney Dis       Date:  2011-12-23       Impact factor: 8.860

6.  Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.

Authors:  T S Jokiranta; A Solomon; M K Pangburn; P F Zipfel; S Meri
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

7.  Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups.

Authors:  B Sis; M Mengel; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; W M Baldwin; E R Bracamonte; V Broecker; F Cosio; A J Demetris; C Drachenberg; G Einecke; J Gloor; D Glotz; E Kraus; C Legendre; H Liapis; R B Mannon; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; E R Rodriguez; D Seron; S Seshan; M Suthanthiran; B A Wasowska; A Zachary; A Zeevi
Journal:  Am J Transplant       Date:  2010-01-29       Impact factor: 8.086

Review 8.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 9.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

10.  Structural basis for engagement by complement factor H of C3b on a self surface.

Authors:  Hugh P Morgan; Christoph Q Schmidt; Mara Guariento; Bärbel S Blaum; Dominic Gillespie; Andrew P Herbert; David Kavanagh; Haydyn D T Mertens; Dmitri I Svergun; Conny M Johansson; Dušan Uhrín; Paul N Barlow; Jonathan P Hannan
Journal:  Nat Struct Mol Biol       Date:  2011-02-13       Impact factor: 15.369

View more
  9 in total

Review 1.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

2.  The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma.

Authors:  Margarita Semis; Gabriel B Gugiu; Ellen A Bernstein; Kenneth E Bernstein; Markus Kalkum
Journal:  Anal Chem       Date:  2019-05-07       Impact factor: 6.986

3.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

4.  A case report of paraproteinemia-associated pauci-immune glomerulonephritis - a new form of monoclonal gammopathy of renal significance?

Authors:  Robert Rope; Neeraja Kambham; Neiha Arora
Journal:  Clin Nephrol Case Stud       Date:  2017-08-17

Review 5.  Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.

Authors:  Antonio Mastrangelo; Jessica Serafinelli; Marisa Giani; Giovanni Montini
Journal:  Front Pediatr       Date:  2020-05-12       Impact factor: 3.418

6.  Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease.

Authors:  Dalia Mahmoud Eldewi; Alshaymaa M Alhabibi; Hanaa Mohammed Eid El Sayed; Sammar Ahmed Kasim Mahmoud; Sanaa Mohammed El Sadek; Rasha Mahmoud Gouda; Mohammed Abd El Malik Hassan; Amal H Ibrahim; Naglaa F Abd El Haliem
Journal:  Int J Gen Med       Date:  2019-09-16

7.  Proteomic Analysis of Urinary Extracellular Vesicles Reveals a Role for the Complement System in Medullary Sponge Kidney Disease.

Authors:  Maurizio Bruschi; Simona Granata; Giovanni Candiano; Antonia Fabris; Andrea Petretto; Gian Marco Ghiggeri; Giovanni Gambaro; Gianluigi Zaza
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

8.  A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates.

Authors:  Wolfgang Winnicki; Peter Pichler; Karl Mechtler; Richard Imre; Ines Steinmacher; Gürkan Sengölge; Daniela Knafl; Georg Beilhack; Ludwig Wagner
Journal:  PeerJ       Date:  2019-12-16       Impact factor: 2.984

Review 9.  Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.

Authors:  Marion Ort; Jasper Dingemanse; John van den Anker; Priska Kaufmann
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.